S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NYSE:TEVA

Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

$12.86
+0.08 (+0.63%)
(As of 04/19/2024 ET)
Today's Range
$12.51
$13.01
50-Day Range
$12.78
$14.44
52-Week Range
$7.09
$14.47
Volume
10.12 million shs
Average Volume
8.55 million shs
Market Capitalization
$14.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.78

Teva Pharmaceutical Industries MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
7.1% Upside
$13.78 Price Target
Short Interest
Healthy
1.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$5.13 M Sold Last Quarter
Proj. Earnings Growth
10.09%
From $2.28 to $2.51 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.61 out of 5 stars

Medical Sector

655th out of 909 stocks

Pharmaceutical Preparations Industry

293rd out of 424 stocks

TEVA stock logo

About Teva Pharmaceutical Industries Stock (NYSE:TEVA)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

TEVA Stock Price History

TEVA Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 5.3%
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
25 Countries with the Lowest Fertility Rates
TEVA Mar 2024 20.000 call
Teva Pharma Industries Ltd ADR (TEVAy)
See More Headlines
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/31/2024
Today
4/21/2024
Next Earnings (Confirmed)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
37,851
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.78
High Stock Price Target
$19.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+7.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-559,000,000.00
Pretax Margin
-3.94%

Debt

Sales & Book Value

Annual Sales
$15.85 billion
Cash Flow
$3.51 per share
Book Value
$7.25 per share

Miscellaneous

Outstanding Shares
1,121,090,000
Free Float
1,114,143,000
Market Cap
$14.42 billion
Optionable
Optionable
Beta
1.05
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

TEVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TEVA shares.
View TEVA analyst ratings
or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price target for 2024?

10 Wall Street analysts have issued 1 year price objectives for Teva Pharmaceutical Industries' shares. Their TEVA share price targets range from $10.00 to $19.00. On average, they expect the company's stock price to reach $13.78 in the next year. This suggests a possible upside of 7.1% from the stock's current price.
View analysts price targets for TEVA
or view top-rated stocks among Wall Street analysts.

How have TEVA shares performed in 2024?

Teva Pharmaceutical Industries' stock was trading at $10.44 on January 1st, 2024. Since then, TEVA stock has increased by 23.2% and is now trading at $12.86.
View the best growth stocks for 2024 here
.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a decrease in short interest in March. As of March 15th, there was short interest totaling 10,460,000 shares, a decrease of 28.9% from the February 29th total of 14,720,000 shares. Based on an average daily trading volume, of 10,530,000 shares, the short-interest ratio is presently 1.0 days.
View Teva Pharmaceutical Industries' Short Interest
.

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TEVA earnings forecast
.

How can I listen to Teva Pharmaceutical Industries' earnings call?

Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, May 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings data on Wednesday, January, 31st. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.25. The company had revenue of $4.46 billion for the quarter, compared to the consensus estimate of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive trailing twelve-month return on equity of 34.90%.

What ETFs hold Teva Pharmaceutical Industries' stock?
What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY24 earnings guidance on Wednesday, January, 31st. The company provided earnings per share (EPS) guidance of $2.20-$2.50 for the period, compared to the consensus earnings per share estimate of $2.41. The company issued revenue guidance of $15.7-$16.3 billion, compared to the consensus revenue estimate of $15.57 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.19%), Bourgeon Capital Management LLC (0.06%), IMC Chicago LLC (0.00%), Financial Sense Advisors Inc. (0.02%), Hennion & Walsh Asset Management Inc. (0.02%) and Range Financial Group LLC (0.01%). Insiders that own company stock include Amir Weiss, David Matthew Stark, Eli Shani, Eliyahu Sharon Kalif, Eric A Hughes, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard D Francis, Sven Dethlefs and Vikki L Conway.
View institutional ownership trends
.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:TEVA) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners